NASDAQ: INZYInozyme Pharma Inc Stock
$4.58-0.07 (-1.51%)
Updated Apr 18, 2024
INZY Price
$4.58
Fair Value Price
-$0.23
Market Cap
$282.92M
52 Week Low
$2.69
52 Week High
$7.80
P/E
-3.34x
P/B
2.01x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$71.17M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.43
Operating Cash Flow
-$71M
Beta
0.78
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
INZY Overview
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how INZY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INZY ($4.58) is overvalued by 2,077.87% relative to our estimate of its Fair Value price of -$0.23 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
INZY ($4.58) is not significantly undervalued (2,077.87%) relative to our estimate of its Fair Value price of -$0.23 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
INZY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more INZY due diligence checks available for Premium users.
Be the first to know about important INZY news, forecast changes, insider trades & much more!
INZY News
Valuation
INZY fair value
Fair Value of INZY stock based on Discounted Cash Flow (DCF)
Price
$4.58
Fair Value
-$0.23
Undervalued by
2,077.87%
INZY ($4.58) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
INZY ($4.58) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
INZY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
INZY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.34x
Industry
15.68x
Market
41.33x
INZY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.01x
Industry
5.76x
INZY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INZY's financial health
Profit margin
Revenue
$0.0
Net Income
-$21.5M
Profit Margin
0%
INZY's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$200.8M
Liabilities
$60.4M
Debt to equity
0.43
INZY's short-term assets ($196.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INZY's short-term assets ($196.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INZY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
INZY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$18.5M
Investing
-$6.5M
Financing
$12.5M
INZY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INZY vs Biotech Stocks
Inozyme Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.